TW200722518A - Sc(fv)2 structural isomers - Google Patents

Sc(fv)2 structural isomers

Info

Publication number
TW200722518A
TW200722518A TW095111608A TW95111608A TW200722518A TW 200722518 A TW200722518 A TW 200722518A TW 095111608 A TW095111608 A TW 095111608A TW 95111608 A TW95111608 A TW 95111608A TW 200722518 A TW200722518 A TW 200722518A
Authority
TW
Taiwan
Prior art keywords
structural isomers
clarified
modification
antibody
composition
Prior art date
Application number
TW095111608A
Other languages
English (en)
Inventor
Tomoyuki Igawa
Hiroyuki Tsunoda
Akiko Koga
Yasufumi Kikuchi
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of TW200722518A publication Critical patent/TW200722518A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW095111608A 2005-03-31 2006-03-31 Sc(fv)2 structural isomers TW200722518A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005101711 2005-03-31
JP2005378467 2005-12-28

Publications (1)

Publication Number Publication Date
TW200722518A true TW200722518A (en) 2007-06-16

Family

ID=37073454

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095111608A TW200722518A (en) 2005-03-31 2006-03-31 Sc(fv)2 structural isomers

Country Status (5)

Country Link
US (1) US9493569B2 (zh)
EP (1) EP1870458B1 (zh)
JP (1) JP5057967B2 (zh)
TW (1) TW200722518A (zh)
WO (1) WO2006106903A1 (zh)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2004033499A1 (ja) * 2002-10-11 2006-02-09 中外製薬株式会社 細胞死誘導剤
US8597911B2 (en) 2003-06-11 2013-12-03 Chugai Seiyaku Kabushiki Kaisha Process for producing antibodies
AU2003271174A1 (en) 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
US20070280951A1 (en) * 2003-12-12 2007-12-06 Naoki Kimura Cell Death Inducing Agents
EP1710255A4 (en) * 2003-12-12 2008-09-24 Chugai Pharmaceutical Co Ltd MODIFIED ANTIBODIES RECOGNIZING A TRIMER OR LARGER RECEPTOR
TW200530269A (en) * 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
WO2005056602A1 (ja) * 2003-12-12 2005-06-23 Chugai Seiyaku Kabushiki Kaisha アゴニスト活性を有する改変抗体のスクリーニング方法
JP4799405B2 (ja) * 2004-04-09 2011-10-26 中外製薬株式会社 細胞死誘導剤
AU2006232287B2 (en) * 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
TW200722518A (en) 2005-03-31 2007-06-16 Chugai Pharmaceutical Co Ltd Sc(fv)2 structural isomers
US8945543B2 (en) 2005-06-10 2015-02-03 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
KR101360671B1 (ko) 2005-06-10 2014-02-07 추가이 세이야쿠 가부시키가이샤 ｓｃ（Ｆｖ）２를 함유하는 의약조성물
EP2009101B1 (en) 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
EP4001409A1 (en) 2006-03-31 2022-05-25 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
CA2657385A1 (en) * 2006-07-13 2008-01-17 Naoki Kimura Cell death inducer
JP5114410B2 (ja) * 2006-08-21 2013-01-09 国立大学法人神戸大学 融合タンパク質の製造方法
CL2008000719A1 (es) * 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
ES2595638T3 (es) 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
PE20090711A1 (es) 2007-09-26 2009-07-15 Chugai Pharmaceutical Co Ltd Region constante de anticuerpo mutante
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
KR102084925B1 (ko) 2008-04-11 2020-03-05 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
JP5787446B2 (ja) 2009-03-19 2015-09-30 中外製薬株式会社 抗体定常領域改変体
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
WO2011037158A1 (ja) 2009-09-24 2011-03-31 中外製薬株式会社 抗体定常領域改変体
EP2543730B1 (en) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
KR102099580B1 (ko) 2010-11-17 2020-04-10 추가이 세이야쿠 가부시키가이샤 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
CN108715614A (zh) 2010-11-30 2018-10-30 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
KR101572338B1 (ko) 2011-02-28 2015-11-26 에프. 호프만-라 로슈 아게 1가 항원 결합 단백질
CA2825081A1 (en) 2011-02-28 2012-09-07 Birgit Bossenmaier Antigen binding proteins
BR112014001573B8 (pt) * 2011-07-22 2022-11-08 Affimed Therapeutics Ag Molécula fv ao antígeno multivalente
EP2787078B1 (en) 2011-10-31 2019-05-22 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
WO2015046467A1 (ja) 2013-09-27 2015-04-02 中外製薬株式会社 ポリペプチド異種多量体の製造方法
KR20160044060A (ko) 2013-10-11 2016-04-22 에프. 호프만-라 로슈 아게 다중특이적 도메인 교환된 통상의 가변 경쇄 항체
US20160280787A1 (en) 2013-11-11 2016-09-29 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified antibody variable region
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
WO2016159213A1 (ja) 2015-04-01 2016-10-06 中外製薬株式会社 ポリペプチド異種多量体の製造方法
US11649262B2 (en) 2015-12-28 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
BR112018068363A2 (pt) 2016-03-14 2019-01-15 Chugai Pharmaceutical Co Ltd fármaco terapêutico indutor de dano celular para uso em terapia de câncer
US11952422B2 (en) 2017-12-05 2024-04-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule comprising altered antibody variable region binding CD3 and CD137
CN109957026A (zh) * 2017-12-22 2019-07-02 成都恩沐生物科技有限公司 共价多特异性抗体
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
EP4263600A1 (en) 2020-12-18 2023-10-25 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity

Family Cites Families (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6094580U (ja) 1983-12-05 1985-06-27 株式会社　銭屋アルミニウム製作所 扉の装飾枠
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP2727112B2 (ja) 1988-04-26 1998-03-11 コニカ株式会社 安定なペルオキシダーゼ組成物及び安定な抗体組成物
US5077216A (en) 1988-07-06 1991-12-31 The Trustees Of Dartmouth College Monoclonal antibodies specific for a human mononculear phagocyte-specific antigen
JPH0341033A (ja) 1989-07-07 1991-02-21 Kyowa Hakko Kogyo Co Ltd 安定なモチリン類含有製剤
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
GB9009548D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5223241A (en) 1990-10-01 1993-06-29 The General Hospital Corporation Method for early detection of allograft rejection
WO1992019759A1 (en) 1991-04-25 1992-11-12 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
GB9120304D0 (en) 1991-09-24 1991-11-06 Erba Carlo Spa Stable pharmaceutical compositions containing a granulocyte macrophage colony stimulating factor
JPH0597703A (ja) 1991-10-04 1993-04-20 Yamanouchi Pharmaceut Co Ltd 改変型組織プラスミノーゲン活性化因子含有組成物
WO1993006862A1 (fr) 1991-10-11 1993-04-15 Toray Industries, Inc. Composition a base d'anticorps
ZA936260B (en) 1992-09-09 1994-03-18 Smithkline Beecham Corp Novel antibodies for conferring passive immunity against infection by a pathogen in man
DE69232604T2 (de) 1992-11-04 2002-11-07 City Of Hope Duarte Antikörperkonstrukte
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
CA2117477C (en) 1992-12-11 2001-06-12 Peter S. Mezes Multivalent single chain antibodies
US5780021A (en) 1993-03-05 1998-07-14 Georgetown University Method for treating type 1 diabetes using α-interferon and/or β-i
US5747654A (en) 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
CZ294359B6 (cs) 1993-09-03 2004-12-15 Chugai Seiyaku Kabushiki Kaisha Monoklonální protilátka způsobující apoptózu buněk kostní dřeně, její fragment, hybridom ji produkující a farmaceutický prostředek, který ji obsahuje
US6719972B1 (en) 1994-06-03 2004-04-13 Repligen Corporation Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
US6048972A (en) 1994-07-13 2000-04-11 Chugai Pharmaceutical Co., Ltd. Recombinant materials for producing humanized anti-IL-8 antibodies
US5885574A (en) 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US8771694B2 (en) 1994-08-12 2014-07-08 Immunomedics, Inc. Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells
DE69534530T2 (de) 1994-08-12 2006-07-06 Immunomedics, Inc. Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
US6451523B1 (en) 1994-09-14 2002-09-17 Interneuron Pharmaceuticals, Inc. Detection of a leptin receptor variant and methods for regulating obesity
DE726075T1 (de) 1995-02-08 1996-12-12 Therapicon Srl Nicht-inorganische pharmazeutische salzige Lösungen zur endonasale Verabreichung
ATE198124T1 (de) 1995-02-28 2001-01-15 Procter & Gamble Herstellung eines kohlensäurefreien getränks mit verbesserter mikrobieller stabilität
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO1996034892A1 (en) 1995-05-03 1996-11-07 Bioenhancements Ltd. Bispecific antibodies in which the binding capability is reversibly inhibited by a photocleavable moiety
EP0835134A1 (en) 1995-05-17 1998-04-15 Regents Of The University Of Minnesota Immunoconjugates comprising single-chain variable region fragments of anti-cd-19 antibodies
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US6013067A (en) 1995-06-07 2000-01-11 Zymogenetics, Inc. Methods for increasing hematopoietic cells
AU6113396A (en) 1995-06-14 1997-01-15 Regents Of The University Of California, The Novel high affinity human antibodies to tumor antigens
DE69635480T2 (de) 1995-06-29 2006-08-17 Immunex Corp., Thousand Oaks Apoptosis induzierendes cytokin
CN1241944C (zh) 1995-09-11 2006-02-15 协和发酵工业株式会社 抗人白介素－5受体α链的抗体
CA2241564C (en) 1996-01-08 2013-09-03 Genentech, Inc. Wsx receptor and ligands
FR2745008A1 (fr) 1996-02-20 1997-08-22 Ass Pour Le Dev De La Rech En Recepteur nucleaire de glucocorticoides modifie, fragments d'adn codant pour ledit recepteur et procedes dans lesquels ils sont mis en oeuvre
EP0903149A4 (en) 1996-03-06 2002-02-13 Chugai Pharmaceutical Co Ltd METHOD FOR SCREENING SUBSTANCES INDUCING APOPTOSIS
ATE267610T1 (de) 1996-03-20 2004-06-15 Immunomedics Inc Glykosylierte igg antikörper
ATE316792T1 (de) 1996-05-09 2006-02-15 Pharma Pacific Pty Ltd Stimulierung wirtseigener abwehrmechanismen gegen krebs
US5908925A (en) 1996-06-27 1999-06-01 Exocell, Inc. Genetically engineered immunoglobulins with specificity for glycated albumin
JP3416035B2 (ja) 1996-09-26 2003-06-16 中外製薬株式会社 ヒト副甲状腺ホルモン関連ペプチドに対する抗体
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6323000B2 (en) 1996-12-20 2001-11-27 Clark A. Briggs Variant human α7 acetylcholine receptor subunit, and methods of production and uses thereof
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
US20040136951A1 (en) 1997-03-17 2004-07-15 Human Genome Sciences, Inc. Death domain containing receptor 5
US7541034B1 (en) 1997-03-20 2009-06-02 The United States Of America As Represented By The Department Of Health And Human Services Recombinant antibodies and immunoconjugates targeted to CD-22 bearing cells and tumors
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6183744B1 (en) 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
JP4213224B2 (ja) 1997-05-02 2009-01-21 ジェネンテック，インコーポレーテッド ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
WO2001036486A2 (en) 1999-11-18 2001-05-25 Oxford Biomedica (Uk) Limited Scfv antibodies against disease associated molecules
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6368596B1 (en) 1997-07-08 2002-04-09 Board Of Regents, The University Of Texas System Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
US5980893A (en) 1997-07-17 1999-11-09 Beth Israel Deaconess Medical Center, Inc. Agonist murine monoclonal antibody as a stimulant for megakaryocytopoiesis
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
HUP0003513A3 (en) 1997-09-11 2004-05-28 Chugai Pharmaceutical Co Ltd Monoclonal antibody inducing apoptosis
US7531643B2 (en) 1997-09-11 2009-05-12 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody inducing apoptosis
CA2273223C (en) 1997-09-29 2003-11-11 Raytheon Company Chip-size package using a polyimide pcb interposer
US5998593A (en) 1998-03-10 1999-12-07 Abbott Laboratories Fluorescent enzyme substrates
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
US7138103B2 (en) 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US7081360B2 (en) 1998-07-28 2006-07-25 Cadus Technologies, Inc. Expression of G protein-coupled receptors with altered ligand binding and/or coupling properties
US6092926A (en) 1998-09-17 2000-07-25 International Business Machines Corporation Thermal monitoring system for semiconductor devices
DE69926647T2 (de) 1998-10-16 2006-11-09 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Durch molekulares pathogenicid vermittelte krankheitsresistenz in pflanzen
US20050220787A1 (en) 2002-11-07 2005-10-06 Lobo Peter I Naturally occuring IgM antibodies that bind to lymphocytes
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
WO2000053634A1 (fr) 1999-03-10 2000-09-14 Chugai Seiyaku Kabushiki Kaisha Fv monocatenaire induisant l'apoptose
US7696325B2 (en) 1999-03-10 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Polypeptide inducing apoptosis
CO5280147A1 (es) 1999-05-18 2003-05-30 Smithkline Beecham Corp Anticuerpo humano monoclonal
DE60028971T2 (de) 1999-06-09 2007-02-08 Genentech, Inc., South San Francisco Apo-2l rezeptor-agonist und cpt-11 synergie-effekt
US20020028178A1 (en) 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
EP1238080A2 (en) 1999-12-14 2002-09-11 The Burnham Institute Bcl-g polypeptides, encoding nucleic acids and methods of use
WO2001064713A2 (en) 2000-03-01 2001-09-07 Christoph Gasche Mammalian interleukin-10 (il-10) receptor variants
TWI241345B (en) 2000-03-10 2005-10-11 Chugai Pharmaceutical Co Ltd Apoptosis inducing polypeptide
CA2404216A1 (en) 2000-03-22 2001-09-27 Curagen Corporation Novel polypeptides, and nucleic acids encoding the same
BR0109705A (pt) 2000-03-31 2005-01-11 Idec Pharma Corp Uso combinado de anticorpos ou antagonistas anti-citocina e anticd20 para o tratamento de linfoma de célula b
CN101289511A (zh) 2000-04-11 2008-10-22 杰南技术公司 多价抗体及其应用
WO2001079494A1 (fr) 2000-04-17 2001-10-25 Chugai Seiyaku Kabushiki Kaisha Anticorps agonistes
US20040058393A1 (en) 2000-04-17 2004-03-25 Naoshi Fukishima Agonist antibodies
DE60035337T2 (de) 2000-05-12 2008-02-28 Gpc Biotech Ag Humane Peptide/Proteine, die das Töten von Zellen, einschliesslich lymphoider Tumorzellen, herbeiführen oder bewirken
JP2004512262A (ja) 2000-06-20 2004-04-22 アイデック　ファーマスーティカルズ　コーポレイション 非放射性抗ｃｄ２０抗体／放射標識抗ｃｄ２２抗体の組合せ
CA2415100A1 (en) 2000-07-12 2002-01-17 Idec Pharmaceutical Corporation Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications
JP5485489B2 (ja) 2000-08-11 2014-05-07 中外製薬株式会社 抗体含有安定化製剤
US7396841B2 (en) 2000-08-18 2008-07-08 Takeda Pharmaceutical Company Limited Injections
MXPA03002262A (es) 2000-09-18 2003-10-15 Idec Pharma Corp Terapia de combinacion para tratamiento de enfermedades autoinmunes usando una combinacion de anticuerpos inmunorreguladores/supresores de celulas b.
EP1327681A4 (en) 2000-10-20 2004-09-01 Chugai Pharmaceutical Co Ltd Degraded agonist antibodies
KR100870123B1 (ko) 2000-10-20 2008-11-25 츄가이 세이야꾸 가부시키가이샤 저분자화 아고니스트 항체
RU2408606C2 (ru) 2000-10-20 2011-01-10 Тугаи Сейяку Кабусики Кайся Соединение - агонист тро
AU2002210917B2 (en) 2000-10-20 2006-05-18 Chugai Seiyaku Kabushiki Kaisha Degraded TPO agonist antibody
AU2002307062A1 (en) 2001-04-02 2002-10-15 Purdue Pharma L.P. Thrombopoietin (tpo) synthebody for stimulation of platelet production
CA2447602C (en) 2001-05-18 2011-11-01 Kirin Beer Kabushiki Kaisha Anti-trail-r antibodies
CN100594935C (zh) 2001-05-25 2010-03-24 人体基因组科学有限公司 免疫特异性结合trail受体的抗体
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
DK1399484T3 (da) 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
US20030148409A1 (en) 2001-10-15 2003-08-07 Edmund Rossi Direct targeting binding proteins
JP3665324B2 (ja) 2001-10-15 2005-06-29 麒麟麦酒株式会社 抗ｈｌａ−ｄｒ抗体
JP2005523888A (ja) 2002-01-03 2005-08-11 ザ スクリプス リサーチ インスティテュート 癌関連エピトープ
KR20040085185A (ko) 2002-02-14 2004-10-07 추가이 세이야쿠 가부시키가이샤 항체함유 용액제제
US20040001828A1 (en) 2002-02-21 2004-01-01 Joseph Tuscano Treatment methods using anti-CD22 antibodies
US20030232887A1 (en) 2002-04-10 2003-12-18 Johnson Douglas Giles Preparation and use of a stable formulation of allosteric effector compounds
ATE512989T1 (de) 2002-04-15 2011-07-15 Chugai Pharmaceutical Co Ltd Verfahren zur herstellung von scdb-bibliotheken
US20050130224A1 (en) 2002-05-31 2005-06-16 Celestar Lexico- Sciences, Inc. Interaction predicting device
WO2003104425A2 (en) 2002-06-07 2003-12-18 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Novel stable anti-cd22 antibodies
CA2488753A1 (en) 2002-06-07 2003-12-18 Immunomedics, Inc. Neutrophil imaging methods in cyctic fibrosis
DE60317677T2 (de) 2002-06-13 2008-10-30 Crucell Holland B.V. Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung
WO2003105782A2 (en) 2002-06-17 2003-12-24 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Specificity grafting of a murine antibody onto a human framework
JPWO2004003198A1 (ja) 2002-06-27 2005-10-27 株式会社ジェノックス創薬研究所 アレルギー性疾患の検査方法、および治療のための薬剤
CN1678634A (zh) 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
JP4489591B2 (ja) 2002-08-27 2010-06-23 中外製薬株式会社 タンパク質溶液製剤の安定化方法
JP2004086682A (ja) 2002-08-28 2004-03-18 Fujitsu Ltd 機能ブロック設計方法および機能ブロック設計装置
KR20050093759A (ko) 2002-09-18 2005-09-23 오르토-맥네일 파마슈티칼, 인코퍼레이티드 혈소판 및 조혈 줄기세포의 생산을 증가시키는 방법
CN1723036A (zh) 2002-09-18 2006-01-18 奥索-麦克尼尔药品公司 增加血小板和造血干细胞产生的方法
JPWO2004033499A1 (ja) 2002-10-11 2006-02-09 中外製薬株式会社 細胞死誘導剤
WO2004037293A1 (ja) 2002-10-22 2004-05-06 Dainippon Pharmaceutical Co., Ltd. 安定化組成物
EP1605058B1 (en) 2003-01-21 2009-05-13 Chugai Seiyaku Kabushiki Kaisha Method of screening light chain of antibody light chains
WO2004081048A1 (ja) 2003-03-13 2004-09-23 Chugai Seiyaku Kabushiki Kaisha 変異受容体に対するアゴニスト活性を有するリガンド
JP2004279086A (ja) 2003-03-13 2004-10-07 Konica Minolta Holdings Inc 放射線画像変換パネル及び放射線画像変換パネルの製造方法
JPWO2004087763A1 (ja) 2003-03-31 2006-07-27 中外製薬株式会社 Ｃｄ２２に対する改変抗体およびその利用
US8597911B2 (en) 2003-06-11 2013-12-03 Chugai Seiyaku Kabushiki Kaisha Process for producing antibodies
CA2545166A1 (en) 2003-11-11 2005-05-19 Chugai Seiyaku Kabushiki Kaisha Humanized anti-cd47 antibody
WO2005056602A1 (ja) 2003-12-12 2005-06-23 Chugai Seiyaku Kabushiki Kaisha アゴニスト活性を有する改変抗体のスクリーニング方法
US20070280951A1 (en) 2003-12-12 2007-12-06 Naoki Kimura Cell Death Inducing Agents
EP1710255A4 (en) 2003-12-12 2008-09-24 Chugai Pharmaceutical Co Ltd MODIFIED ANTIBODIES RECOGNIZING A TRIMER OR LARGER RECEPTOR
TW200530269A (en) 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
TW200530266A (en) 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Method of reinforcing antibody activity
KR20070010046A (ko) 2004-04-06 2007-01-19 제넨테크, 인크. Ｄｒ5 항체 및 그의 용도
JP4799405B2 (ja) 2004-04-09 2011-10-26 中外製薬株式会社 細胞死誘導剤
CA2562771C (en) 2004-04-12 2013-04-09 Medimmune, Inc. Anti-il-9 antibody formulations and uses thereof
TW200605906A (en) 2004-05-11 2006-02-16 Chugai Pharmaceutical Co Ltd Remedy for thrombopenia
CN102731654A (zh) 2004-10-22 2012-10-17 米迪缪尼有限公司 抗hmgb1的高亲和力抗体及其用法
US20090062184A1 (en) 2005-03-24 2009-03-05 Dainippon Sumitomo Pharma Co., Ltd. Fine particulate preparation comprising complex of nucleic acid molecule and collagen
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
TW200722518A (en) 2005-03-31 2007-06-16 Chugai Pharmaceutical Co Ltd Sc(fv)2 structural isomers
EP1927367A4 (en) 2005-05-18 2009-08-12 Univ Tokushima NOVEL PHARMACEUTICAL AGENT BASED ON AN ANTI-HLA ANTIBODY
KR101360671B1 (ko) * 2005-06-10 2014-02-07 추가이 세이야쿠 가부시키가이샤 ｓｃ（Ｆｖ）２를 함유하는 의약조성물
US8945543B2 (en) 2005-06-10 2015-02-03 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
EP1925319B1 (en) 2005-06-10 2018-03-07 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical compositions containing sc(fv)2
WO2006132341A1 (ja) 2005-06-10 2006-12-14 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2部位特異的変異体
CN101410140B (zh) 2006-02-02 2016-10-26 综合医院公司 改造抗体-应激蛋白融合物
EP4001409A1 (en) 2006-03-31 2022-05-25 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
CA2657385A1 (en) 2006-07-13 2008-01-17 Naoki Kimura Cell death inducer
AU2007285217B2 (en) 2006-08-14 2013-02-07 Forerunner Pharma Research Co., Ltd Diagnosis and treatment of cancer using anti-desmoglein-3 antibodies
RU2009126420A (ru) 2006-12-11 2011-01-20 Ф.Хоффманн-Ля Рош Аг (Ch) Парентеральная лекарственная форма антитела к абета
US8722858B2 (en) 2007-06-25 2014-05-13 Chugai Seiyaku Kabushiki Kaisha Anti-Prominin-1 antibody having ADCC activity or CDC activity
SI2234600T1 (sl) 2007-12-21 2014-12-31 F. Hoffmann-La Roche Ag Farmacevtska oblika protitelesa
TW201118166A (en) 2009-09-24 2011-06-01 Chugai Pharmaceutical Co Ltd HLA class I-recognizing antibodies

Also Published As

Publication number Publication date
EP1870458A1 (en) 2007-12-26
JPWO2006106903A1 (ja) 2008-09-11
EP1870458A4 (en) 2009-06-03
EP1870458B1 (en) 2018-05-09
US9493569B2 (en) 2016-11-15
JP5057967B2 (ja) 2012-10-24
WO2006106903A1 (ja) 2006-10-12
US20090297501A1 (en) 2009-12-03

Similar Documents

Publication Publication Date Title
TW200722518A (en) Sc(fv)2 structural isomers
WO2008019061A3 (en) Anti-il-6 monoclonal antibodies and uses thereof
WO2006103100A3 (en) Antibodies against ccr5 and uses thereof
RS54393B1 (en) HUMAN MONOCLONAL ANTIBODIES ON KINASE-1 SIMILAR TO ACTIVE RECEPTOR
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
NZ599683A (en) Anti-ilt7 antibody
RS54624B1 (en) MONOCLONIC ANTIBODIES AGAINST GLIPICAN-3
RS53760B1 (en) HUMAN ANTIBODIES RELATING TO MESOTELINE AND THEIR USES
RS52332B (en) HUMAN ANTI-NGF NEUTRAL ANTIBODIES AS SELECTIVE NGF SIGNAL ROUTE INHIBITORS
WO2006096491A3 (en) Anti-ctla-4 antibody compositions
RS54088B1 (en) B-CELL REDUCTION BY USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES
WO2006071441A3 (en) Antibodies directed to gpnmb and uses thereof
WO2006099698A3 (en) Novel anti-plgf antibody
WO2006012621A3 (en) Compositions and methods for regulating the alternative pathway of complement
WO2006114704A3 (en) P-cadherin antibodies
WO2006066568A3 (de) Monokonale agonistische anti-ctla-4 antikörper
RS53270B (en) MONOCLONAL ANTIBODIES AGAINST AMYLOID BETA PROTEINS AND THEIR USE
WO2008140653A3 (en) Humaneered anti-factor b antibody
MX2011008843A (es) Anticuerpos humanizados que se unen a cd19 y sus usos.
WO2007062245A3 (en) Human monoclonal antibody human cd134 (ox40) and methods of making and using same
NZ607711A (en) Antibodies directed to her-3 and uses thereof
RS54197B1 (en) NEW ANTIBODIES FOR THE INHIBITION OF C-MET DIMERIZATION AND THEIR USE
HRP20090527T1 (en) Nogo-a neutralising immunoglobulins for treatment of neurological diseases
WO2004072266A3 (en) Antibody affinity engineering by serial epitope-guided complementarity replacement
WO2006124269A3 (en) Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders